Pluri Inc
NASDAQ:PLUR

Watchlist Manager
Pluri Inc Logo
Pluri Inc
NASDAQ:PLUR
Watchlist
Price: 3.08 USD -4.35% Market Closed
Market Cap: 28.5m USD

Operating Margin

-1 759.3%
Current
Improving
by 4 844.4%
vs 3-y average of -6 603.6%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 759.3%
=
Operating Income
$-23.3m
/
Revenue
$1.3m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 759.3%
=
Operating Income
$-23.3m
/
Revenue
$1.3m

Peer Comparison

Country Company Market Cap Operating
Margin
IL
Pluri Inc
NASDAQ:PLUR
28.5m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
377.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
156.2B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
111.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.6B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.9B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
46.7B USD
Loading...
No Stocks Found

Market Distribution

Lower than 96% of companies in Israel
Percentile
4th
Based on 734 companies
4th percentile
-1 759.3%
Low
-84 760% — -5.8%
Typical Range
-5.8% — 10.9%
High
10.9% — 23 869.1%
Distribution Statistics
Israel
Min -84 760%
30th Percentile -5.8%
Median 4%
70th Percentile 10.9%
Max 23 869.1%

Pluri Inc
Glance View

Market Cap
28.5m USD
Industry
Biotechnology

Pluri Inc is a IL-based company operating in Biotechnology industry. Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The firm's products include PLX-PAD and PLX R18. The firm's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The firm's PLX products are administered using a standard needle and syringe. The firm's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.

PLUR Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-1 759.3%
=
Operating Income
$-23.3m
/
Revenue
$1.3m
What is Pluri Inc's current Operating Margin?

The current Operating Margin for Pluri Inc is -1 759.3%, which is above its 3-year median of -6 603.6%.

How has Operating Margin changed over time?

Over the last 3 years, Pluri Inc’s Operating Margin has increased from -11 549.8% to -1 759.3%. During this period, it reached a low of -16 809.1% on Mar 31, 2023 and a high of -1 659.9% on Jun 30, 2025.

Back to Top